The Fetal Fibronectin Test – A Crucial Prerogative During Pregnancy

The fetal fibronectine test is an FDA-approved, non-invasive testing procedure that aids in identifying the risk of premature delivery in pregnant women. A negative test outcome guarantees 99% assurance that an expectant woman would not undergo delivery within the span of the subsequent fourteen days.

The fetal fibronectin test facilitates doctors in deciding who the most apposite candidate was for medical intercession, while at the same time providing relief for several women that unnecessarily underwent treatment inclusive of strong steroid medications and avoid being hospitalised.

This testing method is an effectual technique in detecting premature birth. ‘FullTerm, The Fetal Fibronectin Test’ as it is known as, is the sole, highly potent self-determining forecaster of preterm delivery at lesser than thirty-two weeks.

For this form of testing to be done, collections could be carried out in the doctor’s clinic, which is quite alike the Pap Smear Test. The test is known to compute the quantity of fetal fibronectin which is the so called ‘adhesive bond’ that is known to hold the fetus in the vagina or in the womb. In ideal conditions, during 22-35 weeks of pregnancy, the amount of fetal fibronectin must be barely discernible.

Prematurity is believed to be the top ranking reason behind the deaths of newborn babies in the United States. The fetal fibronectin test – a Hologic, Inc product, is the highly accurate means when it comes to forecasting which of the pregnant women could have a possibility of having complications that could lead to delivery of babies that could face a myriad of medical conditions following birth.

A novel study performed at the Maternal and Fetal Research Unit of the St.Thomas Hospital located in London was carried out on close to hundred pregnant women that were between 23-34 weeks of gestation that either displayed symptoms or were asymptomatic. Following the use of the fetal fibronectin test done on both the groups, clinicians were requested to ascertain whether the outcome of the test altered the medical supervision and management in their patients.

The rejoinders obtained from the clinicians suggested that fetal fibronectin test displayed the potentiality in altering the medical management in close to ninety percent of the cases. The conclusion drawn from the fetal fibronectin test was that it was an effectual means of improving risk analysis and had a major impact on the medical choices inclusive of steroid administration, raising scrutiny or cerclage involvement in the high-risk bracket populace included in the study that did not display any symptoms.

Popularity: 1% [?]